Catalyst Pharmaceuticals Comments on Recent Decision by Health Canada to Re-issue an NOC for Ruzurgi®
28 juin 2021 16h30 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., June 28, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
Catalyst Pharmaceuticals Announces Exclusive License and Supply Agreement with DyDo Pharma for the Development and Commercialization of Firdapse® in Japan
28 juin 2021 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., June 28, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
Catalyst Pharmaceuticals, Inc.’s and KYE Pharmaceuticals’ Lawsuit in Canadian Federal Court Quashes the Notice of Compliance (NOC) for Ruzurgi®
03 juin 2021 13h20 HE
|
Catalyst Pharmaceuticals, Inc.
- Without an NOC, Ruzurgi® is without a Marketing Authorization in Canada - Matter Remanded Back to Health Canada to Provide a More Transparent Record of Its Decision in Light of Firdapse®’s Data...
Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences
19 mai 2021 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., May 19, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,...
Catalyst Pharmaceuticals Announces First Quarter 2021 Financial Results and Provides Business Update
10 mai 2021 17h29 HE
|
Catalyst Pharmaceuticals, Inc.
-Firdapse® Q1 2021 Net Revenues of $30.2 Million -First Quarter 2021 GAAP Net Income of $7.7 Million; Non-GAAP Net Income of $11.6 Million -Recently Received Orphan Drug Designation for Firdapse® in...
Catalyst Pharmaceuticals to Hold First Quarter 2021 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, May 11th, 2021
03 mai 2021 08h05 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., May 03, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,...
Catalyst Pharmaceuticals Announces $40 Million Share Repurchase Program
22 mars 2021 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., March 22, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing...
Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update
15 mars 2021 17h26 HE
|
Catalyst Pharmaceuticals, Inc.
- Firdapse® Q4-20 Net Revenues of $31.0 Million, FY-20 Net Revenues of $119.1 Million - GAAP Net Income of $75.0 Million for Fiscal Year 2020 - $140.3 Million in Cash and Investments and No Funded...
Catalyst Pharmaceuticals to Hold Fourth Quarter and Year-End 2020 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, March 16th, 2021
04 mars 2021 11h00 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., March 04, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and...
Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2021
22 févr. 2021 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
Catalyst Supporting Facebook Live Panel on Living with a Rare Disease Hosted by The MightyCatalyst Kicks off Rare Reason Campaign CORAL GABLES, Fla., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Catalyst...